Lamivudine for patients with chronic hepatitis B and advanced liver disease.

By Y. Liaw, J. Sung, W. Chow, G. Farrell, Cha‐Ze Lee, H. Yuen, T. Tanwandee, Qihui Tao, K. Shue, O. Keene and 3 more. New England Journal of Medicine, 2004

2,299 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e58ebc022a60647632d6598f602fbe4b1819dd3a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Lewis R. Roberts
2. J. D. Yang
3. Z. Goodman
4. G. Dusheiko
5. X. Forns
6. J. Pawlotsky

In Hepatology

1. Lewis R. Roberts
2. D. Moradpour
3. J. D. Yang
4. Z. Goodman
5. G. Dusheiko
6. X. Forns
7. J. Pawlotsky

Citations in the corpus

• Magnetic Resonance Elastography of Liver: Technique, Analysis and Clinical Applications (2013, background): “Active antiviral therapy is strongly recommended in chronic hepatitis B patients with cirrhosis; therefore, it may be meaningful to clinicians to detect early cirrhosis for determining timing of antiviral therapy (5,6).”
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. (2008, neutral): “Nausea 40 (9) 6 (3) Fatigue 36 ( 8 ) 16 (7) Upper abdominal pain 30 (7) 11 (5)”
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, background): “The benefit of long-term therapy in preventing disease progression in patients with advanced fibrosis or cirrhosis also decreased after emergence of rtM204 I/V [71, 77].”
• Hepatocellular carcinoma: a global view (2010, background): “Lamivudine treatment reduces the risk of progression from cirrhosis to HCC in patients with chronic HBV, and this preventive effect has also been seen in patients without liver cirrhosis”